BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38437792)

  • 21. Change in therapeutic management after the EndoPredict assay in a prospective decision impact study of Mexican premenopausal breast cancer patients.
    Villarreal-Garza C; Lopez-Martinez EA; Deneken-Hernandez Z; Maffuz-Aziz A; Muñoz-Lozano JF; Barragan-Carrillo R; Ramos-Elias P; Moreno B; Diaz-Perez H; Peña-Curiel O; Curiel-Valdez JJ; Bautista-Piña V
    PLoS One; 2020; 15(3):e0228884. PubMed ID: 32160201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health economic analysis of Breast Cancer Index in patients with ER+, LN- breast cancer.
    Gustavsen G; Schroeder B; Kennedy P; Pothier KC; Erlander MG; Schnabel CA; Ali H
    Am J Manag Care; 2014 Aug; 20(8):e302-10. PubMed ID: 25295793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence.
    Zhang Y; Schnabel CA; Schroeder BE; Jerevall PL; Jankowitz RC; Fornander T; Stål O; Brufsky AM; Sgroi D; Erlander MG
    Clin Cancer Res; 2013 Aug; 19(15):4196-205. PubMed ID: 23757354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.
    Andre F; Ismaila N; Allison KH; Barlow WE; Collyar DE; Damodaran S; Henry NL; Jhaveri K; Kalinsky K; Kuderer NM; Litvak A; Mayer EL; Pusztai L; Raab R; Wolff AC; Stearns V
    J Clin Oncol; 2022 Jun; 40(16):1816-1837. PubMed ID: 35439025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer.
    Albanell J; Svedman C; Gligorov J; Holt SD; Bertelli G; Blohmer JU; Rouzier R; Lluch A; Eiermann W
    Eur J Cancer; 2016 Oct; 66():104-13. PubMed ID: 27544930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
    Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
    Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score.
    Jerevall PL; Brock J; Palazzo J; Wieczorek T; Misialek M; Guidi AJ; Wu Y; Erlander MG; Zhang Y; Schnabel CA; Goss PE; Horick N; Sgroi DC
    Breast Cancer Res Treat; 2019 Jan; 173(2):375-383. PubMed ID: 30350269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(10):1-234. PubMed ID: 32284770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of clinicopathological factors on extended endocrine therapy decision making in estrogen receptor-positive breast cancer.
    Chen W; Wu J; Zhu Y; Huang J; Chen X; Huang O; He J; Li Y; Chen W; Shen K; Zhu L
    Front Oncol; 2022; 12():996522. PubMed ID: 36727047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.
    Torres S; Trudeau M; Gandhi S; Warner E; Verma S; Pritchard KI; Petrella T; Hew-Shue M; Chao C; Eisen A
    Oncologist; 2018 Jul; 23(7):768-775. PubMed ID: 29371476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Precision medicine in extended adjuvant endocrine therapy for breast cancer.
    Tesch ME
    Curr Opin Oncol; 2023 Nov; 35(6):453-460. PubMed ID: 37621168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study.
    Kuchel A; Robinson T; Comins C; Shere M; Varughese M; Sparrow G; Sahu A; Saunders L; Bahl A; Cawthorn SJ; Braybrooke JP
    Br J Cancer; 2016 Mar; 114(7):731-6. PubMed ID: 26954715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.
    Gligorov J; Pivot XB; Jacot W; Naman HL; Spaeth D; Misset JL; Largillier R; Sautiere JL; de Roquancourt A; Pomel C; Rouanet P; Rouzier R; Penault-Llorca FM;
    Oncologist; 2015 Aug; 20(8):873-9. PubMed ID: 26112003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of PONDx, a prospective multicenter study of the Oncotype DX
    Curtit E; Vannetzel JM; Darmon JC; Roche S; Bourgeois H; Dewas S; Catala S; Mereb E; Fanget CF; Genet D; Forest AM; Bernier C; Pivot X
    Breast; 2019 Apr; 44():39-45. PubMed ID: 30634106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A study of the impact of the 21-gene breast cancer assay on the use of adjuvant chemotherapy in women with breast cancer in a Mexican public hospital.
    Bargallo JE; Lara F; Shaw-Dulin R; Perez-Sánchez V; Villarreal-Garza C; Maldonado-Martinez H; Mohar-Betancourt A; Yoshizawa C; Burke E; Decker T; Chao C
    J Surg Oncol; 2015 Feb; 111(2):203-7. PubMed ID: 25288020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
    Henry NL; Somerfield MR; Abramson VG; Ismaila N; Allison KH; Anders CK; Chingos DT; Eisen A; Ferrari BL; Openshaw TH; Spears PA; Vikas P; Stearns V
    J Clin Oncol; 2019 Aug; 37(22):1965-1977. PubMed ID: 31206315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.
    Levine MN; Julian JA; Bedard PL; Eisen A; Trudeau ME; Higgins B; Bordeleau L; Pritchard KI
    J Clin Oncol; 2016 Apr; 34(10):1065-71. PubMed ID: 26598746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Oncotype DX testing on adjuvant treatment decisions in patients with early breast cancer: a single-center study in the United Arab Emirates.
    Jaafar H; Bashir MA; Taher A; Qawasmeh K; Jaloudi M
    Asia Pac J Clin Oncol; 2014 Dec; 10(4):354-60. PubMed ID: 25243360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.
    Schwedhelm TM; Rees JR; Onega T; Zipkin RJ; Schaefer A; Celaya MO; Moen EL
    BMC Cancer; 2020 Sep; 20(1):847. PubMed ID: 32883270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.